Search

for
Search:

Sort by

Research

30 / 1000+ results

Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)

research Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)

November 2025 in “SKIN The Journal of Cutaneous Medicine”

Upadacitinib effectively treats severe alopecia areata and is safe.

research Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study

February 2026 in “Journal of Dermatological Treatment”

CG2001 is safe and well-tolerated for treating hair loss, with fewer side effects than oral finasteride.

A Phase IIA Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Selective Androgen Receptor Modulator (SARM), MK-0773 in Female Participants with Sarcopenia

research A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia

211 citations , May 2013 in “Journal of Nutrition Health & Aging”

MK-0773 safely increased muscle mass but did not improve muscle strength or function in elderly women with sarcopenia.

A Randomized, Double-Blind, Placebo and Active Controlled Phase II Study to Evaluate the Safety and Efficacy of Novel Dutasteride Topical Solution (0.01%, 0.02%, and 0.05% w/v) in Male Subjects With Androgenetic Alopecia

research A Randomized, Double-Blind, Placebo and Active Controlled Phase II Study to Evaluate the Safety and Efficacy of Novel Dutasteride Topical Solution (0.01%, 0.02%, and 0.05% w/v) in Male Subjects With Androgenetic Alopecia

August 2025 in “Cureus”

The 0.05% dutasteride topical solution effectively promotes hair growth with fewer side effects than oral treatments.

A Spermidine-Based Nutritional Supplement Prolongs the Anagen Phase of Hair Follicles in Humans: A Randomized, Placebo-Controlled, Double-Blind Study

research A spermidine-based nutritional supplement prolongs the anagen phase of hair follicles in humans: a randomized, placebo-controlled, double-blind study

8 citations , October 2017 in “Dermatology practical & conceptual”

A spermidine-based supplement may help hair grow longer by keeping it in the growth phase.

Efficacy and Safety of Topical Finasteride Spray Solution in the Treatment of Chinese Men with Androgenetic Alopecia: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

research Efficacy and safety of topical finasteride spray solution in the treatment of Chinese men with androgenetic alopecia: A phase III, multicenter, randomized, double-blind, placebo-controlled study

March 2025 in “Chinese Medical Journal”

Topical finasteride effectively and safely increases hair growth in men with hair loss.

Efficacy, Safety, and Tolerability of Dutasteride 0.5 mg Once Daily in Male Patients with Male Pattern Hair Loss: A Randomized, Double-Blind, Placebo-Controlled, Phase III Study

research Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: A randomized, double-blind, placebo-controlled, phase III study

92 citations , June 2010 in “Journal of The American Academy of Dermatology”

Dutasteride 0.5 mg daily improves hair growth safely in men with hair loss.

research Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial

3 citations , October 2021 in “Clinical, Cosmetic and Investigational Dermatology”

Setipiprant did not significantly improve hair growth in men with hair loss.

Sublingual Minoxidil for the Treatment of Male and Female Pattern Hair Loss: A Randomized, Double-Blind, Placebo-Controlled, Phase 1B Clinical Trial

research Sublingual minoxidil for the treatment of male and female pattern hair loss: a randomized, double‐blind, placebo‐controlled, phase 1B clinical trial

5 citations , August 2021 in “Journal of The European Academy of Dermatology and Venereology”

Sublingual minoxidil safely promotes hair growth.

research 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial

2 citations , September 2023 in “Journal of the American Academy of Dermatology”

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

research Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trial

March 2026 in “British Journal of Dermatology”

Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.

Safety, Tolerability, and Pharmacokinetics of CG2001 in Chinese Adult Male Subjects With Androgenetic Alopecia: A Randomized, Double-Blind, Placebo-Controlled, Single- and Multi-Dose, Phase 1 Clinical Study

research Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study

January 2026

CG2001 is safe, well-tolerated, and a promising treatment for hair loss with fewer side effects.

research Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study

January 2026

CG2001 is safe and well-tolerated for treating hair loss in men.

Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata

research Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata

October 2025 in “Dermatology and Therapy”

Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.

Oral Spermidine Supplementation Prolongs Hair Follicle Anagen Phase with Sustained Effects: A Randomized, Double-Blind, Placebo-Controlled Trial

research Oral Spermidine Supplementation Prolongs Hair Follicle Anagen Phase with Sustained Effects: A Randomized, Double-Blind, Placebo-Controlled Trial

January 2025 in “MEDS Public Health and Preventive Medicine”

Spermidine supplements can help extend the hair growth phase and may be useful for treating hair loss.

research 724 - A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin in adults with severe to very-severe alopecia areata

August 2024 in “British Journal of Dermatology”

Rezpegaldesleukin shows promise for treating severe alopecia areata.

research Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double‐blind, placebo‐controlled trial

48 citations , July 2023 in “Pediatric Dermatology”

Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.

research Phase 2, double-blind, randomized, placebo-controlled study of the safety and efficacy of elagolix in women with polycystic ovary syndrome

2 citations , February 2023 in “F&S Reports”

Elagolix did not effectively treat polycystic ovary syndrome.

research 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials

2 citations , September 2024 in “Journal of the American Academy of Dermatology”

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

Efficacy and Safety of Baricitinib in Adult Patients With Severe Alopecia Areata With or Without an Atopic Background From Two Randomized, Placebo-Controlled, Phase 3 Trials

research 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials

3 citations , September 2022 in “Journal of the American Academy of Dermatology”

Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.

research Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study

January 2025

Topical GT20029 effectively promotes hair regrowth and is well-tolerated for treating androgenetic alopecia.

research Supplementary Material for: Autologous Cell Therapy for Aged Human Skin: A Randomized, Placebo-Controlled, Phase-I Study

January 2019

RCS-01 cell therapy is safe and improves skin gene expression.

research Autologous Cell Therapy for Aged Human Skin: A Randomized, Placebo-Controlled, Phase-I Study

6 citations , September 2019 in “Skin pharmacology and physiology”

RCS-01 therapy is safe and may improve skin structure by affecting gene expression.

research Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies

1 citations , November 2023 in “SKIN The Journal of Cutaneous Medicine”

research 42134 Long-term Efficacy of Guselkumab (GUS) on Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study in Biologic-naïve Patients With Psoriatic Arthritis (PsA)

September 2023 in “Journal of the American Academy of Dermatology”

Guselkumab effectively reduces fatigue in Psoriatic Arthritis patients over two years.

research 022 Randomized, double-blind, placebo-controlled, single-centre, phase I safety study of intradermal injections of autologous fibroblasts isolated from the non-bulbar dermal sheath of the hair follicle to treat skin aging

September 2017 in “Journal of Investigative Dermatology”

RCS-01 is safe and may help rejuvenate aging skin.

research The selective androgen receptor modulator GTx‐024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double‐blind, placebo‐controlled phase II trial

306 citations , August 2011 in “Journal of cachexia, sarcopenia and muscle”

Enobosarm significantly increased muscle mass and improved physical function in elderly men and postmenopausal women without serious side effects.

research Effects of Dehydroepiandrosterone Therapy on Pubic Hair Growth and Psychological Well-Being in Adolescent Girls and Young Women with Central Adrenal Insufficiency: A Double-Blind, Randomized, Placebo-Controlled Phase III Trial

49 citations , January 2009 in “The Journal of Clinical Endocrinology & Metabolism”

DHEA treatment helps grow pubic hair and boosts mood in girls with adrenal issues.

research Efficacy and Safety of SER120 Nasal Spray in Patients with Nocturia: Pooled Analysis of 2 Randomized, Double-Blind, Placebo Controlled, Phase 3 Trials

21 citations , April 2018 in “The Journal of urology/The journal of urology”

SER120 nasal spray effectively reduces nighttime urination and is safe for patients.

research Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study

December 2025 in “Journal of Dermatological Treatment”

GT20029 helps regrow hair in men with hair loss and is well-tolerated.